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CMM cutaneous malignant melanoma 
UM uveal malignant melanoma 
DN dysplastic nevi 
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LN lymph node 
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SNBO SNB not done 
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SNB+ SNB histologically positive 
ELND elective lymph, node dissection 
DLND delayed lymph node dissection 
SLND selectively lymph node dissection 
RLA radical lymphadenectomy 
LMM lentigo maligna melanoma 
SSM superficial spreading melanoma 
NM nodular melanoma 
ALM acro-lentiginous melanoma 
AMM amelanotic melanoma 
TNM Tumour-Node-Metastasis 
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S.C. subcutaneous 
MU Million Unit 
DTIC dacarbazine 
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MCi milliCurrie 
DN+ dysplastic nevi bearing CMM patient 
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Once considered a rare tumour, cutaneous malignant melanoma (CMM) is now 
recognised as a leading cause of morbidity and mortality, and its frequency is rapidly 
increasing. It can occur on any cutaneous surface, as well as in eyes and on mucous 
membranes 1;2. Although it is considered a very aggressive tumour, its biological behaviour is 
heterogeneous. 
The incidence of invasive CMM among Caucasians in the United States is about 11 
cases per 100 000 inhabitants per year and in Europe 3-14 3. 
The risk of melanoma is inversely related to distance from the equator: in England there are 
only three new cases per 100 000 inhabitants per year, and the highest reported rate 46 per 
100 000 is from Queensland, the most equatorial of Australian States >; 2; 4. Fair skinned 
Caucasians are at grater risk, than those who have darker skin. The lower risk is found among 
black and Asian populations 5. The incidence of melanoma has increased dramatically over 
time. The rapid rise in incidence among recent birth cohorts has led to a relative 
predominance of melanoma among young adults 6. CMM rarely occurs prior to puberty but 
when it does occur about 50 % of cases arise in giant congenital nevi1. 
Mortality rates have also been analysed in many countries, and the findings parallel those of 
incidence. 
In CMM, the most commonly identified mutation is found in the tumour suppressor 
gene family. Recessive germline CDKN2A mutations have been found in 30% to 50% of 
members of melanoma kindred, in 8% to 15% of individuals with multiple primary 
melanomas and in some sporadic CMM. Mutations in the cyclin-dependent kinase CDK4 has 
also been identified in a few melanoma families. However, at least 60% of melanoma families 
have neither of these mutations 8"'°. Many studies have characterised the phenotypic features 
of individuals who are at increased risk for developing CMM 12. Melanoma is five times 
more common in individuals with fair or red hair, blue eyes and fair skin and markedly more 
frequent in those people, who react to sunlight by burning rather than tanning 13~17. Congenital 
and many common acquired nevi are also associated with higher risk for susceptibility of 
cutaneous melanoma 18"25. By far the strongest association is with the presence of atypical or 
dysplastic nevi (DN). 
The DN is both a precursor of and a very important risk factor for melanoma. The 
dysplastic nevus syndrome (DNS) was described by Clark 26 and Lynch 27 related to the 
familial melanoma. Since its first description, it has been a subject of controversy, the main 
areas of argument being the exact clinical and pathological criteria required to make the 
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diagnosis 28. These nevi may be seen in patients in a sporadic or a familial setting, and their 
true biological significance is still under debate. The sporadic form29 is more common. 
In 1984 a NHI Consensus Conference 30 suggested that patients with DN could usefully be 
divided into four categories on the basis of personal and family involvement (Table I.). This is 
a useful working classification as the risk of malignant melanoma is raised very little above 
baseline in the A category but by several hundredfold in the D category. 
TABLE I. Melanoma risk related with personal and family history 
Multiple DN Personal history Family history Family history 
Patient of CMM of multiple DN ofCMM 
A No No No 
B No Yes No 
C Yes No Yes 
D Yes Yes Yes 
The clinical feature of DN is characteristic (Fig. 1). They may have an irregular shape 
with indistinct border and asymmetric pigmentation. Within the macular lesion an eccentric 
nodule may be palpable. The size and number of lesions are variable. They can be localised 
on any part of the skin surface. Predilection sites are the upper trunk and especially the back. 
Characteristic feature is the involvement of the non-sun exposed areas such as the buttocks 
and scalp (Fig. 2) 21. DN, usually compound, is identified on histological examination by the 
presence of architectural atypia (lentiginous melanocytic hyperplasia, bridging of junctional 
nests and focal elongation of epidermal rete ridges) and by cytological atypia of the nevus 
cells (Fig. 3). 
In our previous studies we have determined that the frequency of atypical moles is 
increased not only in cutaneous, but in uveal melanoma patients: DN patients are at increased 
risk of developing both cutaneous and uveal melanoma 31'3S. We have also found that uveal 
melanoma patients with DN are at increased risk developing prognosticaliy worst 
(epitheloid/mixed) histological forms of uveal malignant melanoma 36; 37. Ophthalmic 
examinations of our DN bearing patients revealed markedly more frequent pigmented ocular 
alterations among individuals harboring cutaneous dysplastic nevi compared to non-dysplastic 
population38. The prognostic importance of the presence of DN in the course of CMM is not 
clarified. 
Figure 2. Multiple dysplastic nevi appeared on the back of a patient with dysplastic nevi 
syndrome (DNS). 
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Figure 3. Malignant transformation of a DN with histological signs of regression (H&E) 
(5 x objective) 
Early recognition and prompt excision of primary CMM is the course of action most 
likely to improve the patient's survival prospects. If CMM is diagnosed when it is an early 
melanoma (<lmm) the cure rate is close to 100 %, in contrast with advanced diseases, where 
iq jn 
the life prospect is close to 0% ' . The course of malignant melanoma is characterised by 
early dissemination. Metastasis usually occurs at first through the lymphatics into the 
surrounding skin or into the regional lymph nodes. The recurrences are developed in distant 
sites by haematogenous route in one third of metastatic cases. 
At present, there is no agreed view on the optimal procedure for treating melanoma. 
Generally, the position is that malignant melanomas should be treated by surgery. 
As far as possible, extensive three-dimensional surgical removal of the primary tumour is 
performed with resection margin into the healthy tissue and down to the fascia, which is not 
excised. Over the past decade the recommended resection margins for melanomas of varying 
thickness have been reduced (Table II.) 40-44"46. 
TABLE II. Tumour thickness and safety margin 
Tumour thickness (mm) Safety margin (cm) 
In situ 0.5 
<2 m m 1 
>2 m m 2-3 
Surgery remains the only effective option in the treatment of nodal metastasis from 
CMM since chemotherapy and radiotherapy do not achieve the same cure rate in patients with 
nodal disease. However, the indication for performing an elective lymph node dissection 
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(ELND) or a delayed one (DLND) is contested 47. Morton et al. 48 therefore developed a 
minimally invasive, intraoperative lymphatic mapping technique that should allow more 
precise pathologic staging before deciding to perform radical dissection 49"52. Using this 
diagnostic procedure, patients could be distinguished with clinically occult nodal disease from 
those whose lymph nodes are tumour-free 53; 54. Radical lymphadenectomy (RLA) is then 
confined to those in the former group, introducing in this way the concept of selective 
dissection (SLND) in contrast to ELND and DLND of the past. The lymphatic mapping 
technique uses a blue dye and subsequently this dye together with a radioactive agent to trace 
the path of lymph, as it flows from the primary to nodes in the regional lymphatic drainage 
basin. If the melanoma has metastasised, tumour cells are most likely to be found in the 
lymph node on the lymphatic drainage channel closest to the site of the primary melanoma. 
The "sentinel" node (SN) is the first in the regional basin to stain as the dye enters the 
lymphatic basin. It can then be removed for immediate pathologic staging before decision is 
made to go ahead and perform RLA 49; 50; 52; 5S. 
Accuracy and safety of this technique are now largely documented. All the reported 
experiences indicate that the SN is the lymph node most likely to harbour metastatic 
melanoma 53; 54; 56. The precise indication of SNB in CMM and biological evidence of the 
nodal micrometastasis are questionable. 
The treatment modalities have not been dramatically changed in the past decades in 
metastatic melanoma. Various approaches have been used in treating of distant metastases S7~ 
s9. All four major therapeutic modalities- surgery, chemotherapy, immunotherapy and 
radiation therapy-may be helpful in appropriate circumstances, but most patients with 
advanced disease die from the internal organ involvement. 
Excellent prognostic information can be obtained from clinical features and 
histological examination of CMM (Table III.). Advanced age and male gender have been 
associated with an adverse prognosis60;61. Anatomical site is an important clinical prognostic 
determinant. Histological types are usually correlating with survival. 
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TABLE III. Histological types of CMM 
1. LMM lentigo maligna melanoma (Fig. 4. Al) 
2. .SSM superficial spreading melanoma (Fig. 4. A2, Fig. 5.) 
3. NM nodular melanoma (Fig. 4. Bl) 
4. ALM acro-lentiginous melanoma (Fig .4. B2) 
5. AMM amelanotic melanoma (Fig. 4. C2) 
Al,2 
âjfih 
MFï; • H F ^ " 1 " 
m 
Bl,2 
Cl,2 
Figure 4. 
A1 LMM on the ear 
B1 SSM with nodular part 
CI NM on the lower eyelid 
A2 Early SSM 
B2 ALM on the toe 
C2 AMM on the trunk 
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Figure 5. Clinical (A) and dermatoscopical (B) picture of the SSM with regression 
The Breslow thickness, the most important single predictor of prognosis, is defined as 
a distance between the granular layer of the epidermis and the deepest melanoma cells. The 
relation of thickness to survival has been expressed in inverse ratio ' . The Clark level 
reflects the depth of invasion 64. In most cases the invasion correlates well with the thickness. 
Increased mitotic rate and ulceration of the primary tumour are poor prognostic signs. 
Microscopic satellitosis and vascular invasion of tumour cells have also been associated with 
unfavourable prognosis. 
Definition of tumour regression and lymphocytic reaction has been variously defined 
by different pathologists 65. Lymphocytic infiltration of vertical growth phase of the tumour 
may indicate a favourable prognosis, whereas complete regression of a portion of the tumour 
may associate with a relatively poor survival rate. Recently it was determined, that beside the 
tumour thickness, the regional lymph node involvement is the most powerful predictor for the 
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disease outcome in CMM. This fact has induced the changing of Tumour-Node-Metastasis 
(TNM) classification in 2002. The new TNM defines the pathological staging of the regional 
lymph nodes66'67. 
Despite of all these well-known classical prognostic factors CMM is an unpredictable disease 
with a capricious biologic behaviour. 
Regarding the mentioned serious consequences of the disease, considerable efforts has 
been made to identify the intrinsic end extrinsic risk factors and prognostic markers to 
determine the most endangered population. Despite the presently available selection of the 
risk population it is important to further clarify new powerful predictors, which could 
influence the therapy and the disease outcome in CMM. 
Aims of the study 
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I. To characterise the main classical prognostic factors and the course of the disease in 
our melanoma patient population: 
gender 
age of onset of melanoma 
location of the primary tumours 
histological types 
invasion rate 
thickness of the tumour 
clinical stages of the disease 
second malignancies 
survival 
II. To compare the main prognostic factors and survival in melanoma patients with or 
without dysplastic nevi. 
III. To study the main prognostic factors and course of disease in melanoma patients in 
relation with the histology of sentinel nodes. 
IV. To clarify the predictive value of different tumour parameters for the risk of sentinel 
node involvement in melanoma cases. 
Patients and methods 
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I. Evaluation of main prognostic factors in all CMM patients treated between 1970 and 
2000 
General management of CMM patients 
The study group consisted of 1803 patients with CMM, who were treated between 1970 and 
2000 at the Department of Dermatology and Allergology, the University of Szeged. Dermato-
oncological Program computerised database was acquired to retrospectively identify the data 
of patients. 
The following data were recorded: 
A. Demographic 
Age at onset 
Gender 
Home address 
B. Clinical findings 
Location of the primary tumour 
Palpable lymph nodes 
C. Surgical 
Method of primary tumour removal 
Lymph node dissection 
D. Histological findings 
Histological type 
Tumour thickness 
Invasion rate 
Lymph node involvement 
E. Dissemination rate: stage of the disease by using TNM classification UICC 1987. 
(Table IV.) 
F. Course of disease and survival 
Second malignant tumours 
The clinical diagnosis was histologically verified in every case. The majority of these 
patients underwent wide local excision of the primary CMM. Until late the 90s, the safety 
zones were 3 cm in impalpable lesions and 5 cm were in thick (palpable) tumours with skin 
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grafting. Intraoperative frozen-section biopsies were histologically examined in questionable 
cases. 
Usually we have performed the operations under general anaesthesia. Our previous 
concept in the treatment of non-palpable regional lymph nodes was to apply ELND. Initially 
we have performed ELND in all of those patients who had primary CMM of 1.5 mm or 
thicker and/or infiltrating the reticular dermis (Clark level III). Palpable nodes were indication 
for RLA (Fig. 6) We have changed our therapeutic management of CMM based on new data 
in the literature (Fig. 7). The safety margins were decreased for 1-2 cm related to the risk of 
melanoma (Table II). Excision margins were based on clinical assessment of tumour 
thickness. Our current policy in surgical treatment of regional nodes is to use SLND (see in 
part of SNB technique). The technique of SLND is presented as a rational and practical 
technical alternative to ELND or wait-and-watch treatment of patients with medium/high risk 
melanoma without palpable nodes. 
The majority of the histologically node positive cases were treated with dacarbazine 
# 2 (DTIC) monochemotherapy. The drug was given in a dose of about 250mg/m body surface 
for 5 days at 4 weeks intervals by intravenous route. 
BOLD regimen (bleomycin, oncovin, lomustine/carmustine, DTIC) was used to treat patients 
with metastatic disease in other organs. Other polychemotherapies, and chemoimmunotherapy 
(DTIC-Fotemustine, DTIC- cysplatin,DTIC-Bleomycin DTIC-IFNa) were applied in several 
cases. In the last decade, immunotherapy was used in selected cases with nodal involvement 
or high-risk primary tumour without metastasis. Interferon alpha (IFNa) 2a and 2b were given 
in different dosages based on the indication of the therapy and tolerance of patients (3-10 MU 
s.c. t.i.w. during half to 2 years). 
TABLE IV. TNM classification of malignant melanoma (UICC 1987) 
Stage I A P L No M0 
Stage I B PT2 N„ M0 
Stage II pTj N„ M„ 
Stage III pT4 N„ M„ 
all pT N u M„ 
Stage IV all pT all N M, 
V*3 
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Management of melanoma at the Department of Dermatology and Allergology, 
University of Szeged 
(1970-1998) 
Clinical diagnosis: CMM 
General anaesthesia 
Wide excision (3-5 cm safety margin) +grafting 
i 
Histology 
i 
Breslow>1.5mm/Clark III-IV 
Observation 
Breslow<1.5mm, Clark II 
ELND (non-palpable nodes) 
TLND (palpable nodes) 
Negative 
4 
Observation 
Histology 
Positive 
Chemotherapy 
Figure 6. 
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Management of melanoma at the Department of Dermatology and Allergology, 
University of Szeged 
After 1998 
Clinical diagnosis: CMM 
low risk 
i 
high risk 
General anaesthesia 
4 
Narrow excision (1cm) 
Breslowdmm, Clark III 
Observation 
Wide excision (2cm)+SNB 
Histology 
Breslow>lmm,ulcerated,regressive,Clark IV 
SNB negative SNB positive 
RLA 
Histology 
Negative 
i 
Positive 
INFoc Chemotherapy 
Figure 7. 
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II. Evaluation of prognostic value of cutaneous DN in CMM patients 
This part of the dissertation consists the analysis of 665 selected CMM patients treated 
between 1990 and 1997 at our department. The same data were recorded as in part I and 
completed with personal and family history of DN. 
Clinical diagnosis of DN in patients with CMM 
DN was diagnosed with clinical inspection that included the dermatoscopy and skin 
surface microscopy (epiluminescent microscopy) in all patients with melanoma, who were 
treated after 1990 at the Department of Dermatology. Our criteria for diagnosis of DN were: 
irregular border, asymmetry, irregular pigmentation, macular part within the pigmented 
lesion, size bigger than 0.5 cm ' . Dermatoscopical examination enabled us to 
differentiate DN from thin melanomas or other benign melanocytic nevi 68 '69. Dermatoscopy 
allows examination of pigmented lesions in vivo on the body surface at a moderate 
magnification of 10-to lOOx, using oil to render the surface epidermis translucent. 
Those patients classified as DN-bearing patient, who had 10 or more atypical moles. We have 
distinguished two groups within the DN+ cases based on family history of DN. 
In several cases the clinical diagnosis of DN was confirmed by histological examinations. 
III. Predictive value of different tumour parameters for the risk of SN involvement in 
melanoma patients 
In the third part of the dissertation 244 CMM patients treated between 01/01/1999 and 
31/12/2000 were evaluated. During this time SN was removed together with primary tumours 
of 1 mm or thicker, ulcerated or regressive, based on clinical appearance, in 120 melanoma 
cases. Our database was completed with the histological findings about the ulceration and 
regression of the primary tumours and the SN examination for this period. 
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Surgical removal of the SN 
The SNB technique is currently used by many melanoma centres to evaluate the 
presence of clinically inapparent microscopic metastases in the first draining lymph node in a 
nodal basin. 
-Preoperative dynamic lymphoscintigraphy (LC) was done in every patient who 
underwent SNB (Fig .8) It was helpful to define lesions with more than one draining nodal 
basin. This was carried out by intradermal, perilesional injection of 0,5 mCi Tc-99 labelled 
sulfur colloid (Amersham Shorin). Continuous imaging with a large field view gamma 
camera was performed, depending on location of the CMM, for up to 2.5 hours for axial 
tumour sites with potentially equivocal lymphatic drainage 70. 
-Under general anaesthesia 0,5-2 ml of blue dye (patent blue 50 mg sulpharum 
coeruleum, Byk Gulden) was injected intradermally around the lesion or into the site of the 
primary tumour. (Fig. 9) 
-A hand-held gamma probe was used to identity the greatest radioactivity within the 
draining lymphatic basin over which the skin excision was made. The primary indicator of SN 
was the visual blue colour. 
SNs were considered those, which appear dyed by the tracer or those which counts 
were 15 to 20 fold the counts of background tissues. When significant residual activity was 
registered in the operating field, additional SNs were searched for. 
Figure 8. Praeoperative lymphoscintigraphy 
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Figure 9. Intracutaneous patent blue injection around the primary tumour 
Figure 10. Intraoperative picture of the blue sentinel node 
Histological examination of SN 
Once the SN was removed, it was fixed in buffered 10% formalin for paraffin 
embedded sections to stain with Hematoxylin and Eosin (H&E) (Fig. 11). Lymph nodes 
negative for metastasis by this analysis had additional sections stained with 
immunohistochemical markers to S 100 (DAKO) (Fig. 12), HMB 45 (DAKO) (Fig. 13) 
and/or Melan A (DAKO). Histologically, melanoma as small aggregates of single cells or 
group of cells appeared in subcapsular location in most cases. These cells were then by 
careful cytologic evaluation differentiated from nevus cells and by immunohistochemical 
staining from macrophages. S-100 positive dendritic cells can be recognised by their dendritic 
appearance and benign nuclear characteristics. SN with evidence of metastasis by light 
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microscopy or immunohistochemical analysis were considered positive, and SLND was 
performed (or recommended) on the involved basin(s). In our cases the PCR technique was 
not applied for evaluation of metastatic cells 50. 
IV. Statistical analysis 
Statistical analysis was carried out using the Statistical Package for the Social Sciences 
(SPSS) biostatistical computer program. 
m its : 
¡. Vi -, ft 41 • f 
Figure 13. Melanoma metastasis in sentinel node (H&E staining) (5x objective) 
Figure 14. Melanoma metastasis in sentinel node by immunohistochemistry with S-100 
(5x objective) 
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Figure 15. Groups of metastatic melanoma cells in the sentinel node by 
immunohistochemistry (HMB-45) (lOx objective) 
Results 
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I. Evaluation of main prognostic factors in all CMM patients treated between 1970 and 
2000 
In the last three decades 1802 CMM patients were treated at our Department. Among 
these cases 777 were male and 1025 were female. The mean age of the CMM patient 
population was 53.6 years (range, 13-98 years). The current increasing incidence of CMM can 
also be observed in our region in Hungary. Figure 16 demonstrates well that in the last three 
decades the increase in incidence was about eightfold in Szeged. We have relatively exact 
data in our town. In the last year 17 new CMM cases were diagnosed per 100 000 inhabitants. 
As can be seen on the diagram, there was a peak in 1996 probably because awareness and 
screening programs were initiated at that time. 
Figure 16. Incidence of CMM in Szeged (n=414) ( „: 1985-1989 data are not presented) 
25 
20 
15 
10 
5 
0 
P a t i e n t s N o . 
Figure 17. Number of CMM treated between 1970 and 2000 in periods of 5 years 
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The absolute number of the treated patients has also increased dramatically over the 
time. Distribution of CMM patients treated in 5-year periods is shown in Fig. 17. 
The locations of primary tumours in both sexes are shown in Fig. 18. The most 
frequent site of primaries in the male population was the trunk in contrast with females, where 
the majority of CMM localised on the lower limbs. 
• male 
• female 
head trunk limbs acral mm. occult 
Figure 18. Locations of the primary tumours in patients with CMM (n=1802) (%) 
The frequencies of the different histological types of primary tumours are shown in 
Fig. 19. The dominant histological type of primary tumour in both sexes was the SSM, 
however numerous NM were also found. 
Figure 19. Distribution of histological types of CMM (n=1802) (%) 
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The maximum thickness of primary melanoma varied as can be seen in Fig. 20. 
About two-thirds of the tumours were thicker than 1.5 mm, which had medium or high risk 
for the development of metastases. 
y <0,75mm 
• 0.76-1,5mm 
• 1.51-4.0mm 
• <4.1mm 
• unknown 
Figure 20. Distribution of Breslow thickness in CMM patients % (n=1802) 
Primary tumours were also classified on the basis of the depth of tumour invasion in 
both sexes. These groups are shown in Fig 21. Most tumours have infiltrated the reticular 
dermis or invaded deeper elements of the cutaneous / subcutaneous tissues. 
• CI.I 
•ci.II 
•a.in 
• CI.IV 
• CI.V 
• NC 
43% 
Figure 21. Distribution of invasion rate of CMM patients (%) (n=1802) 
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The stage distribution (according to TNM classification, UICC 1987) of melanoma 
cases is demonstrated on Fig 22. As can be seen in this diagram, the typical stage was stage 
III in both sexes. At present, among the 1802 cases 941 patients lives 559 patients were 
deceased and another 302 are lost to the follow up. The least follow up period was one year. 
• male 
• female 
Figure 22. Stage distribution of CMM patients (n=l 802) 
Stage related survival rates are demonstrated on Figure 23, 24 and 25. Among those 
patients whose primary tumour was thinner than 4 mm without nodal or distant metastasis the 
overall survival was about 90 %. On the other hand, with regional nodal involvement (stage 
III) or distant metastasis (stage IV) the survival rate were found much worse (58 to 10 %). 
Survival Functions (both sexes) stadium 
•4 4 
«H-
0 
•n: 
4i- 4H—i h 
4-h-
H h 44 1 +-
10 15 
H h 
, 1 1 h 
D IV. 
+ IV.-censored 
111.-censored 
II.-censored 
D l./B 
l./B-censored 
I./A 
l./A-censored 
20 
y e a r s 
Survival Functions: Females stadium 
V. 
V.-censored 
ll.-censored 
I.-censored 
JB 
./B-censored 
./A 
l./A-censored 
0 10 15 20 
y e a r s 
Survival Functions: Males stadium 
£ L L„ —f- t-
t H i- j 
H F 1 h 
iü-t-
—i 1 1 1 1 : 1 1 i 1 r 
0 5 10 
0 IV. 
IV.-censored 
I.-censored 
II.-censored 
D l./B 
+ l./B-censored 
I./A 
l./A-censored 
i i i I ' r~" 
15 20 
y e a r s 
30 
II. Evaluation of the prognostic value ofDNin CMMpatients 
In order to investigate the prognostic value of cutaneous DN, the age, location, 
dissemination rate, second primaiy tumors and survival were compared in CMM patients with 
or without DN. The study group consisted of 665 selected patients (393 female and 272 
male), treated between 1990 and 1997, whose data were collected retrospectively from our 
computerized database. The mean age of these cases was 55.57 years (range 14-94 years). 
From a minimum of 10 to 100 DN were found in 148 (22,25 %) of the 665 cases, and 15 
patients (2.25%) had more than 100 cutaneous DN. These 163 patients were considered to be 
DN-bearing individuals. Within this DN+ group, only 25 patients (15.33%) had a positive 
family history for DN without CMM occurring in the family. The difference between the ages 
of onset of tumour in the compared groups was significant in both sexes. Both the 
DN+ females and males were much younger (by 19.34 years for the females and 9.19 years 
for the males) than the DN- group at the time of detection of CMM (Table V). Both univariate 
analysis and the Mann-Whitney test indicated that the differences were significant (p<0.001). 
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TABLE V. Age of onset in CMM patients with and without DN 
Gender DN-bearing Mean age of onset of Number 
CMM patients CMM (yrs + SD) of patients 
Male DN- 60.28 (13.55) 197 
DN+ 50.36 (14.58) 75 
*DN+ 1 51.45(13.90) 67 
**DN+ 2 41.25 (17.90) 8 
Total 57.54 (14.51) 272 
Female DN- 58.53 (14.36) 305 
DN+ 39.18 (13.58) 88 
*DN+ 1 39.78(13.66) 81 
**DN+ 2 32.29(11.27) 7 
Total 54.20 (16.32) 393 
502 
148 
15 
665 
DN-: Dysplastic nevi absent 
DN+: Dysplastic nevi present 
*DN+ 1: number of DN 10-100 
**DN+ 2: number of DN >100 
SD: standard deviation 
Both sexes DN- 59.22 (14.06) 
*DN+ 1 45.06 (14.91) 
**DN+ 2 37.07 (15.36) 
Total 55.57 (15.68) 
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The other prognostic factors were analyzed in 619 patients (360 female and 249 male) 
from among the 665, whose follow-up time was at least 5 years. 
CMM was located on the trunk more frequently in the DN+ females than in DN-
females (Table VI), in whom the characteristic location was the lower limbs p<0.001). 
TABLE VI. Location of primary tumors in female DN- and DN+ CMM patients 
Location of the primary CMM 
DN-bearing of 
CMM patients H T L A M Unknown Total 
DN+ No. 6 41 27 1 0 2 77 
patients (%) 7.8 53.2 35.1 1.3 0 2.6 100 
DN- No. 56 70 133 15 3 6 283 
patients % 19.8 24.7 47.0 5.3 1.1 2.1 100 
Total No. 62 111 160 16 3 8 360 
% 17.2 30.8 44.4 4.4 0.8 2.2 100 
DN+ = DN present, DN- = DN absent 
H = head & neck, T = trunk, L = limbs, A = acral, M = mucosal 
(%2 p<0.001) 
In contrast, essential differences were not found between the location of CMM in the 
DN- and DN+ male groups (Table VII) 
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TABLE VII. Location of primary tumors in male DN- and DN+ CMM patients 
Location of the primary CMM 
DN-bearing of 
CMM patients H T L A M Unknown Total 
DN+ No. 1 47 13 1 0 2 64 
patients % 1.6 73.4 20.3 1.6 0 3.1 100 
DN- No. 29 106 42 4 1 3 185 
patients % 15.7 57.3 22.7 2.2 0.5 1.6 100 
Total No. 30 153 55 5 1 5 249 
% 12.0 61.4 22.1 2.0 0.4 2.0 100 
DN+ = DN present, DN- = DN absent 
H = head & neck, T = trunk, L = limbs, A = acral, M = mucosal 
Figs 26. and 27. demonstrate that significant differences were not found in the 
distribution of the CMM stages (UICC 1987) in the compared groups for either males or 
females p>0.05). 
However, analysis of the frequency of non-skin second malignancies revealed an 
extremely large difference between the DN+ and DN-free groups. 14.1% of the DN+ patients 
had second malignant tumors, as compared with 3.3% of the DN- patients (Table VIII). The 
most frequent second tumor in the DN+ patients was CMM, in contrast with the DN- cases, 
whose second malignancies (with only low incidence) were other solid tumors. Double 
primary melanomas were found in 17 of the 148 DN+ patients, in 3 further cases more than 2 
CMMs were diagnosed. A 28-year-old male had 8 SSM, and 2 males suffered from triple 
melanoma. 
Comparison of the stage-related survival rates demonstrated the survival benefit of the 
presence of DN. The subgroups consisted of relatively small numbers of patients with DN, 
which did not allow conclusions of great statistical significance. These data were also difficult 
to compare because of the extremely large difference in the mean ages of the groups. 
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Figure 26. Distribution of stages in female CMM patients with and without DN (%) n=360 
Figure 27. Stage distribution of DN+ and DN- male patients with melanoma (%) n=259 
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TABLE VIII. Second primary tumours in melanoma patients with or without DN 
Patients Melanoma Other 
malignancies 
DN+ 163 21 (12.88%) 2 (1.22%) 
DN- 502 1 (0.20%) 16(3.18%) 
(* pcO.OOl) (*p>0.05) 
*Fischer's exact test 
III. Predictive value of different tumour parameters for the risk of SN involvement in 
melanoma patients 
In the present study the data of 244 selected patients with CMM treated between 
01/01/1999 and 31/12/2000 were analysed retrospectively. In the past two years we have 
removed the SNs together with primary tumours of 1mm or thicker, ulcerated and regressive, 
based on clinical appearance, in 120 melanoma cases. The thickness, ulceration and 
regression of the primary CMM in relation with the histology of SNB were evaluated. The 
distribution of the histological types of the primary CMMs is demonstrated in Table IX. 
TABLE IX. Distribution of the histological types of melanomas. 
LMM SSM NM ALM AMM OTHER OCCULT 
Patients 21 134 51 12 3 18 5 
In the histological findings the regression and ulceration were graded as present or 
absent. All patient had non-palpable regional lymph nodes by clinical examination. During 
this study period at least 1 SN was successfully localised and harvested in all of the cases. 
Among the 120 cases with CMM 128 SNs were considered. The locations of SNs and the 
primary CMMs are shown in Table X and XI. 
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TABLE X. Location of the primary melanomas and the histology of sentinel nodes 
H T UL LL A MM Other All 
Patients 
SNB 0 32 31 20 25 5 6 5 124 
SNB - 2 23 11 24 1 0 1 62 
SNB + 1 34 12 9 1 0 1 58 
All 35 88 43 58 7 6 7 244 
H = head, T = trunk, UL = upper limbs, LL = lower limbs, A = acral 
TABLE XI. Location of sentinel nodes and their histology 
SNB Axillar Inguinal Other Total 
SNB - 35 34 l 70 
SNB + 34 19 5 58 
Total 69 53 6 128 
Of the 120 patients 58 (48,3%) had involved SN with metastatic cells. As can be seen 
in table XII, our data demonstrates a significant positive correlation between SNB positivity 
and increasing tumour thickness (x2=62.595; df=8.p<0.001) 
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TABLE XII. Correlation between tumour thickness (mm) and the histology of sentinel 
node(s) 
Thickness 
Patients 0,001-1 (mm) 1,001-2 (mm) 2,001-4 (mm) 4< (mm) Other 
SNBO 63 14 11* 17* 19 
% 70.7 31.1 22 42.5 95 
SNB - 15 20 20 7 0 
% 16.9 44.4 40 17.5 0 
SNB + 11 11 19 16 1 
% 12.4 24.5 38 40 5 
Total 89 45 50 40 20 
% 100 100 100 100 100 
* Patients with palpable lymph nodes or distant metastasis and/or serious concomitant 
diseases 
Ulceration required the localised total absence of epidermis. Among the 224 primary 
CMMs 84 (37,5%) were ulcerated. The histological sign of ulceration was more frequent in 
thicker tumours, therefore correlated well with SN positivity (Table XIII) 
TABLE XIII. Correlation between sentinel node positivity, tumour thickness (mm) and 
ulceration 
Ulcerated Non ulcerated Total 
Tumour thickness 0,001-2 2,001< 0,001-2 2,001< 
SNB0/- 9 45 103 10 167 
SNB+ 3 27 19 8 57 
Total (%) 12 (5.4) 72 (32.1) 122 (54.5) 18(8) 224*(100) 
* 5 occult primary melanoma and 15 unclassified for ulceration 
By our criteria the definition of regression to have prognostic significance must 
include the presence of a zone of tumour-free epidermis and dermis, in which there is fibrosis, 
often along with inflammation and dilated vessels, flanked on one or both sides by tumour. 
After the histological examination of the primary tumours the signs of regression were found 
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among the patients with thin (<2mm) CMM (n=134, Table XIV). The relative risk for the 
involvement of SN in patients with regressive CMM was near tenfold higher compered to the 
cases with non-regressive tumours (Relative risk: 9.779, 95% Confident interval: 3.560-
26.862) 
TABLE XIV Correlation between sentinel node positivity and histological signs of 
regression 
Regressive Non-regressive Total % 
SNB 0/- 8 95 103 76 
SNB + 14 17 31 23 
Total (%) 22 (16.4) 112 (83.6) 134 100 
In cases of histologically positive SN we have recommended for the patients the 
lymphadenectomy of the basin. Of 58 SNB positive patients in 52 cases SLND were 
performed. Among the 52 patients who underwent SLND additional nodal involvement were 
found in 24 (46,15%) cases. 
These results are summarised in Table XV. 
TABLE XV. Number of positive lymph nodes (LN) in patients with selective lymph node 
dissection 
LN number 1 LN 2 LNs 2<LNs involvement 
Cells/group of cells 5 8 4 
Metastasis> 2mm 3 3 1 
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Although the follow up period is very short, of the 62 SN negative patients only 3 
cases have developed metastasis. The clinical characteristics of these three patients are listed 
in Table XVI. 
TABLE XVI. Characteristics of sentinel node negative patients with tumour progression 
Number of patients 1. 2. 3. 
Sex/Age (year) F/36 F/56 F/50 
Localisation of the primary tumour leg leg arm 
Histological type SSM SSM SSM 
Invasion rate II III IV 
Thickness (mm) 0,89 1,56 2,97 
Ulceration 0 + + 
Regression 0 0 + 
Site of recurrence RLN in transit RLN 
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Discussion 
Adl. 
CMM represents a significant and growing public health burden worldwide. 
Approximately 42 000 cases of CMM and 40 000 cases of in situ CMM were diagnosed in 
2000 in the United States 1; 2; 4; 22. In the 1930s, the lifetime risk of an American developing 
invasive CMM was 1 in 1500. Currently, that risk is 1 in 74. Hence, this neoplasm is 
responsible for the loss of more years of life than might be expected on the basis of its 
associated mortality. 
According to the reorganised Hungarian Cancer Registry there were about 1000 new 
melanoma cases at the same period in Hungary. The calculated incidence rate of CMM was 
about 10 per 100 000 inhabitants in 2000 in Hungary. In contrast, in our database we have 
revealed 17 new CMM cases in Szeged at the same period. Though the annual number of 
hours of sunshine is the highest in Hungaiy (it is more than 2000 hours), this itself can't 
account for the relevant difference between these two values. Among our patients the 
proportion of in situ primary tumours was absolutely low. In our previous studies the 
relatively low incidence of CMM observed in south eastern Hungary during a 20-year period 
between 1970 and 1990 may be a consequence either of a poorer diagnosis of early cases, or a 
truly lower incidence71;72. Because of the dramatically increasing incidence in the last decade 
worldwide and the great proportion of high-risk tumours at presentation in Hungaiy we 
believe that a considerable number of primary tumours in an early stage are probably missed, 
and therefore the relatively low incidence observed in Hungary is not realistic. 
Many authors have reported female preponderance of CMM. The male to female ratio 
of 1:1.319 in our series is only slightly greater than the overall sex ratio for CMM in the 
general populations in other part of the world. The mean age at first diagnosis in our series 
was 53.6 years. This is similar to previous reports of CMM 67. 
Early recognition and immediate treatment have resulted in a rise in the overall five 
year survival rate for all stages of disease from 60% in 1960 to 1963 to 83% in 1977 to 1982 
in the United States. Considering that in Hungaiy 360 patients have died of melanoma in 
2000, and the 1000 new diagnosed CMM, our results of five-year survival rate for all stages is 
approached approximately 60%57; 67; 73. 
At the first clinical examination, most' patients were free of palpable nodal 
involvement or distant metastases, but the proportion of thick, deeply invading primary 
tumours was high, greater than 60%. The majority of our cases were in stage III, which 
means, that most of our cases had thicker tumours than 4 mm and/or had the regional nodal 
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involvement. Balch et al. reported the prognostic factor analysis of 17 600 patients with 
CMM. In that multi-institutional series about 70% of all cases had 2 mm or thinner tumours 
67'. Several other authors have demonstrated similar data. These findings also indicate a 
deficiency in the early recognition of CMM in Hungary 22; 74. 
The most frequent anatomical locations of the primary tumours in man were the back 
and acral regions, while in women it was the leg. These data and the distribution of 
histological types of primary tumours are similar to the observations of several other authors 
43; 67 
Comparison of the stage related survival rates of our CMM cases and the data of other 
cancer centres have not revealed considerable differences in stage I A-B and Stage IV. 
Survival rates in stage II and III were more favourable in our cases 43; 61. In our previous 
clinical practice, the implementation of ELND has given an accurate pathological selection 
between node negative and node positive CMM patients. This upstaging has resulted an 
apparent survival benefit both in stage II and in stage III. Previously, Szekeres et al. have 
reported similar data about the importance of ELND in patients with primary CMM with 
intermediate risk (tumour thickness between 1.5 and 4 mm) 71. Our department has 
participated in an international multicenter randomised trial that was carried out by the WHO 
Melanoma Programme from 1982 to 1989 47. The trial included patients with trunk melanoma 
1.5 mm or more in thickness. Multivariate analysis showed that routine use of ELND had no 
impact on survival, whilst the status of regional nodes affected survival significantly. The 
patients with regional nodes that became clinically and histologically positive during follow 
up had the poorest prognosis. Node dissection offers increased survival in patients with node 
metastasis only. These data have suggested the therapeutic benefit of SLND. 
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Ad 2. 
In the improvement of the early recognition of CMM it is fundamental to screen the 
risk population. At the same time that we are seeing a rise in the incidence of CMM, there is a 
growing awareness that many or most melanoma deaths may be prevent by the screening of 
individuals at high risk. The purpose of screening high-risk individuals is twofold: to remove 
or closely monitor high-risk, pigmented cutaneous lesions that are potential precursors of 
melanoma and to diagnose melanoma in an early phase, before metastases have developed. 
It is well known that one of the most relevant and sensitive phenotypic markers of 
increased melanoma risk is the presence of DN, but numerous other potential risk factors have 
also been cited. Included among these are acute and blistering sunburn, certain phenotypic 
factors, immunosuppression, prior therapy with psoralen with UV A light, UV exposure at 
tanning beds, elevated socio-economic status and history of CMM in a first-degree-
relative 7; 13"17; 75'79. Furthermore, people who have had one CMM are at higher risk of 
developing another. 
In our previous studies we have found that the relative risk for uveal melanoma in 
patients with DN was similar to the relative risk of CMM in patients with DN. These results 
suggest that the presence of DN may be used as a sign of the gene carrier status not only for 
skin but also for uveal melanoma34"37. 
In the present study, the prognostic factors and the survival times of melanoma 
patients with and without DN were compared. Melanoma developed 19.34 years, and 9.19 
years earlier in female and male DN+ patients, respectively. 21 of the 163 DN+ patients, 
while only 1 of the 502 DN- patients suffered from multiple primary melanomas80. 
Analyses of the prognostic factors of patients with multiple primary melanomas have 
been published by other groups 10; 81"86. In all of these studies it was reported that the group 
with DN was approximately 10 to 21 years younger than the group without DN. The 
frequency of DN in patients with multiple melanomas in previously reported studies was 
between 38% and 48%. Our results also demonstrate a significant difference between the 
mean ages of DN- and DN+ patients with CMM, and a high frequency of multiple melanomas 
in the DN+ groups. Thus, DN should be considered a risk factor for the development of 
melanoma at a relatively young age. 
In conclusion, our findings confirm that patients with DN syndrome are indeed 
genetically disposed to develop CMM. Special emphasis should therefore be placed on the 
early and regular screening of patients with this important risk factor. 
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Ad 3. 
The AJCC recently proposed major revisions of the TNM categories and stage 
groupings for CMM using evidence-based methodology. The proposed staging system better 
reflects independent prognostic factors that are used in clinical trials and in reporting the 
outcomes of various melanoma treatment modalities. Major revisions include: 
(1) melanoma thickness and ulceration to be used in T category but not the level of 
invasion (except for T1 melanomas); 
(2) the number of metastatic LN to be used in the N category rather than their gross 
dimensions and the delineation of clinically occult (microscopic) versus clinically apparent 
(i.e. macroscopic) nodal metastases; 
(3) the site of distant metastasis and the presence of elevated serum lactic 
dehydrogenase (LDH) to be used in the M category; 
(4) an upstaging of all patients with stage I to III when the primary tumour is 
ulcerated; 
(5) a merging of satellite metastases around a primary CMM and in transit metastases 
into a single staging entity that is grouped into stage III disease 
(6) a new convention for defining clinical and pathological staging so as to take into 
account the new staging information gained from intraoperative lymphatic mapping and SNB 
66; 67;87 
In this new AJCC melanoma staging system Balch et al. have confirmed that the 
metastatic involvement of regional lymph nodes is the most powerful prognostic predictor in 
CMM. 
After the controversial elective lymph node dissection (ELND) and delayed lymph 
node dissection (DLND) the implementation of the novel technique sentinel lymph node 
biopsy (SNB) should make it possible to better select the high-risk patients for nodal 
involvement. The SNB has become widely established in several countries as a technique for 
prognostic assessment. The surgical procedure is not complicated and has a relatively low 
morbidity, however, the indications for SNB are still a matter of debate. 
The decision to surgically stage regional LNs should be based on several factors, 
including sensitivity of the diagnostic procedure, the likelihood of finding occult metastasis, 
the impact of such findings on treatment, and other clinical and psychosocial issues. The 
questionable populations among the CMM cases are the patients with thin melanomas. 
Although metastatic involvement in patients with thin primary melanoma is rare, there have 
been several reported cases88; 89. Previous reports have suggested using SNB in patients with 
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primary tumour 1 mm or thicker, ulcerated and deeply invasive (Clark level IV.)46; 50; 53; 54; 56; 
70; 90-97 
Our policy was to use SLND in those patients who had primary tumours 1 mm or 
thicker, ulcerated or regressive on clinical appearance. After the learning phase the rate of 
successful SNs localisations increased to 100% using the combination of preoperative 
lymphoscintigraphy and intraoperative lymphatic mapping with both vital blue dye and radio 
colloid. 
In our series the sentinel node positivity rate was 48,3%. This is much higher than the 
findings of other groups 98-1 The positive correlation of SNB positivity with tumour 
thickness is expected and generally has been observed. Other groups have found ulceration of 
the primary tumours between 10% and 25%. In our study we have found ulcerated CMM in 
37.4%. The high rate of nodal involvement in our series could be associated both with the 
precise pathological examinations and the grater proportion of high-risk tumours with 
ulceration. 
Melanomas showing histological evidence of regression are in some cases to be 
associated with worse clinical course than similar but non-regressing tumours 90; 101. Partial 
regression of primary tumours has been documented in up to 20 % of the cases, even 
complete spontaneous regression has been observed. The regression may be decreasing the 
thickness of the tumour, which becomes relatively thinner, but as it seems the survival 
correlates with the original tumour thickness. The definition and judgement of regression are 
debated, whilst the precise pathomechanism of regression is unknown. It seems to be an 
immunological reaction of the host against the tumour. These reasons may explain the 
controversy of this area both in pathology and immunology. 
Our findings have revealed high rate SN involvement also in the group of patients with 
thin, but regressive melanomas. We found the predictive value of tumour regression in thin 
tumours for the risk of nodal disease significantly high. 
134 melanoma patients with a primary tumour thickness of 2.0 mm or less were 
treated at the Department of Dermatology, University of Szeged, from January 1, 1999, 
through December 31, 2000. Following preoperative lymphoscintigraphy (Tc-99m nanocoll) 
and lymphatic mapping, sentinel nodes were successfully identified in all cases using both 
blue dye and radiolabeled colloid with a gamma probe. Both primaiy tumours and sentinel 
nodes were analysed histologically on paraffin embedded specimens on serial sections using 
haematoxylin and eosin staining and immunohistochemistry with HMB 45 and S-100 
antibodies by two well-trained dermatopathologists independently. By our criteria the 
definition of regression must include the presence of a zone of tumour-free epidermis and 
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dermis, in which there is fibrosis, often along with inflammation and dilated vessels, flanked 
on one or both sides by tumour (the estimated specificity and sensitivity were over 90%). 
Among the one hundred and thirty-four melanoma patients (primary CMM is less than 
2mm thick) thirty-one patients (23%) had positive SNB. There were eighty-nine patients with 
CMM less than 1 mm thick, of which twelve (13.5%) had positive sentinel node (specificity 
99% and sensitivity 96%) The patients in our study underwent follow-up visits every three 
months. The median follow up was 36 months (range: 24-48 months). 
Sentinel node metastases were found in a significantly greater proportion among 
patients with primary tumours showing histological evidence of regression: 14/22 (63.6%) vs. 
17/112 (15.2%) positive cases in patients with regressing and non-regressing melanomas, 
respectively. The relative risk of sentinel node-positivity for patients with regressing tumours 
was 9.779 (95% CI 3.56-26.862) as compared to patients with non-regressing tumours. 
Furthermore, of the 14 sentinel node-positive patients with regressing melanomas, 11 had 
tumours thinner than 1.0 mm (mean 0.682+ 0.20, range between 0.380 and 0.912 mm), and 
none of these ulcerated or infiltrated deeper than the papillary dermis (Clark's level II). 
These findings indicate that early in their disease course, patients with relatively thin 
but regressing melanomas are at an almost ten times higher relative risk of developing 
regional lymph node metastases than are patients with non-regressing melanomas. It is 
tempting to speculate that histological regression results in a decreased Breslow's thickness 
measurement, and thus in some cases an erroneously more favourable prognostic estimate. 
Although melanoma regression has been reported to be associated with higher metastatic 
potential 88, to date no direct evidence has been published to the effect that histological 
regression predicts increased risk of nodal involvement. Currently for patients with primary 
melanoma less than 1.0 mm thick, SNB is only indicated if ulceration or deep infiltration 
(Clark's level IV-V) is present50. 
Our results suggest that patients with thin melanomas showing histological signs of 
regression should be considered as potential candidates for sentinel lymph node biopsy. 
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Conclusions 
1. CMM represents a significant and growing public health burden in Hungary just as it 
does worldwide. Our findings reveal that our CMM patients have thicker primary 
tumours and more advanced disease than the CMM patients in western countries. 
These findings indicate a deficiency in the early recognition of CMM in Hungary. 
Prevention and early detection remain the primary goals in the war against this cancer. 
Professional education, public awareness, patient education and research advances 
should and must improve the survival prospects of our patients. 
2 To achieve early recognition of CMM, the most important strategy is to screen the 
high-risk population both for cutaneous and uveal melanoma therefore, the DN+ 
melanoma patients have to be included in the focus of our interests since they 
represent an increased clinical risk population. Our results indicate that DN is the most 
significant factor that warrants increased surveillance of such patients to detect and 
treat melanoma in its early and curable stage. Our findings revealed that the DN 
bearing melanoma patient population is much younger at the time of first diagnosis of 
CMM compared to the DN free individuals. Multiple CMMs were also more frequent 
among the DN+ melanoma cases. These patients should be warned of the potential 
hazards of sun exposure, educated in methods of protecting themselves and their 
children from the sun, and encouraged to do monthly skin self-examinations. Total 
skin examinations at regular intervals should be performed by a trained dermatologist 
at least once a year and should be continued for life in all of DN bearing individuals. 
3 The presence or absence of nodal metastasis is a very sensitive predictor of the 
outcome of melanoma. With the implementation of SNB technique it is possible to 
select melanoma patients with occult nodal disease at an early stage. We have found a 
great proportion of SN positive patients among those cases who had thick, ulcerated 
and/or regressive melanomas regardless of tumour thickness. Our findings indicate 
that tumour regression should be included as a new parameter in the criteria of the 
indication for SNB in patients with thin melanomas. 
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Summary 
Cutaneous malignant melanoma (CMM) represents a significant and growing public 
health burden in Hungary just as it does worldwide. 
The aims of this study were to characterize the main common prognostic factors, 
tumour parameters and survival in our patients treated with cutaneous malignant melanoma. 
These factors were also compared in those melanoma patients who had dysplastic nevi. 
Our findings reveal that melanoma patients in Szeged, Hungary have thicker primary 
tumours and more advanced disease than the melanoma patients in western countries. These 
findings indicate a deficiency in the early recognition of the melanoma in Hungary. 
We have found that the dysplastic nevi bearing melanoma patient population is much 
younger at the time of first diagnosis of melanoma compared to the dysplastic nevi free 
melanoma patients. Multiple cutaneous melanomas were also more frequent among the 
dysplastic nevi bearing melanoma cases. Our results indicate that dysplastic nevus is the most 
significant factor that warrants increased surveillance of such patients to detect and treat 
melanoma in its early and curable stage 
The presence or absence of nodal metastasis is a very sensitive predictor of the 
outcome of melanoma. With the implementation of sentinel node biopsy (SNB) technique it is 
possible to select melanoma patients with occult nodal disease at an early stage. We have 
found a great proportion of sentinel node (SN) positive patients among those cases who had 
thick, ulcerated and/or regressive melanomas regardless of tumour thickness. Our findings 
indicate that tumour regression should be included as a new parameter in the criteria of the 
indication for SNB in patients with thin melanomas. 
To achieve early recognition of CMM, the most important strategy is to screen the 
high-risk population both for cutaneous and uveal melanoma that includes patients who cany 
dysplastic nevi on their skin, since they represent an increased clinical risk population. 
Prevention and early detection remain the primary goals in the war against this cancer. 
Professional education, public awareness, patient education and research advances should and 
must improve the survival prospects of melanoma patients. 
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